Cardio Diagnostics Holdings is trading 6.53% up at $2.12 after filing an investor presentation highlighting its commercialization strategy, AI-powered cardiovascular tests, and $854 CMS reimbursement rate.
- The company is scheduled to host an investor call on August 20, 2026, covering reimbursement progress, clinical studies, and growth initiatives.
- The broader healthcare sector is strong, while major U.S. indexes are lower, making the presentation and call the clearer catalysts.
- The move remains active during regular trading.